Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13342847 | 1.00 | CAPN1 (0.38) | CAPN1ALDH1A1MDM2ALOX15NPC1 | |
| SCHEMBL233300 | 0.88 | MDM2 (0.47) | CAPN1ALDH1A1MDM2ALOX15NPC1 | |
| SCHEMBL13928511 | 0.88 | MDM2 (0.47) | CAPN1ALDH1A1MDM2ALOX15NPC1 | |
| SCHEMBL3224249 | 0.82 | MDM4 (0.44) | MDM2LMNA | |
| SCHEMBL3264342 | 0.82 | MDM4 (0.44) | MDM2LMNA | |
| SCHEMBL12629195 | 0.80 | PTPN1 (0.34) | ALDH1A1MDM2ALOX15MAPTMEN1 | |
| SCHEMBL30431821 | 0.79 | MDM2 (0.49) | MDM2MEN1KMT2APTPN1 | |
| SCHEMBL19296186 | 0.78 | MDM2 (0.43) | MDM2KMT2APTPN1 | |
| SCHEMBL20597255 | 0.78 | MDM2 (0.43) | MDM2KMT2APTPN1 | |
| SCHEMBL38666359 | 0.76 | MDM2 (0.53) | ALDH1A1MDM2ALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885MDM2 1786/4885 |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885MDM2 1786/4885 |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885MDM2 1786/4885 |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885MDM2 1786/4885 |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CAPN1 4252/4885ALDH1A1 3456/4885MDM2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.